Development of Renal Cysts after Crizotinib Treatment in Advanced ALK-Positive Non–Small-Cell Lung Cancer

Lin, Yen‐Ting; Wang, Yufen; Yang, James Chih‐Hsin; Yu, Chong‐Jen; Wu, Shang‐Gin; Shih, Jin‐Yuan; Yang, Pan‐Chyr

doi:10.1097/jto.0000000000000326

Cited by 56 publications

(75 citation statements)

References 13 publications

(8 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A series from Taiwan found changes in renal cysts in seven (22 %) of 32 patients who received crizotinib for ALK-positive advanced NSCLC [83]. In a recent analysis of 255 patients treated with crizotinib for at least 6 months, 9 % had developed new cysts, and 2 % had both new cysts and size increases in existing cysts of more than 50 % [84].…”

Section: Renal Cystsmentioning

confidence: 96%

Renal Toxicities of Targeted Therapies

et al. 2015

View full text Add to dashboard Cite

With the incorporation of targeted therapies in routine cancer therapy, it is imperative that the array of toxicities associated with these agents be well-recognized and managed, especially since these toxicities are distinct from those seen with conventional cytotoxic agents. This review will focus on these renal toxicities from commonly used targeted agents. This review discusses the mechanisms of these side effects and management strategies. Anti-vascular endothelial growth factor (VEGF) agents including the monoclonal antibody bevacizumab, aflibercept (VEGF trap), and anti-VEGF receptor (VEGFR) tyrosine kinase inhibitors (TKIs) all cause hypertension, whereas some of them result in proteinuria. Monoclonal antibodies against the human epidermal growth factor receptor (HER) family of receptors, such as cetuximab and panitumumab, cause electrolyte imbalances including hypomagnesemia and hypokalemia due to the direct nephrotoxic effect of the drug on renal tubules. Cetuximab may also result in renal tubular acidosis. The TKIs, imatinib and dasatinib, can result in acute or chronic renal failure. Rituximab, an anti-CD20 monoclonal antibody, can cause acute renal failure following initiation of therapy because of the onset of acute tumor lysis syndrome. Everolimus, a mammalian target of rapamycin (mTOR) inhibitor, can result in proteinuria. Discerning the renal adverse effects resulting from these agents is essential for safe treatment strategies, particularly in those with pre-existing renal disease.

show abstract

Section: Renal Cystsmentioning

confidence: 96%

Renal Toxicities of Targeted Therapies

et al. 2015

View full text Add to dashboard Cite

show abstract

“…Lin et al [14] evaluated 32 patients in 3 clinical trial and also found significant reduction in the size of renal cysts after treatment suspension. The patients who had significant renal cyst changes received Crizotinib for longer duration (median, 956 days versus 248 days, p = 0.007).…”

Section: Discussionmentioning

confidence: 99%

“…Crizotinib increases the risk of renal cysts development and also increases pre-existing cystic lesions [12] [14].…”

Section: Discussionmentioning

confidence: 99%

Development of Aseptic Renal Abscess in a Patient with Non-Small-Cell Lung Cancer with ALK Translocation during Crizotinib Treatment

Carvalho¹,

Shimada²,

Neto³

et al. 2015

ALC

View full text Add to dashboard Cite

Background: Crizotinib is a tyrosine kinase inhibitor of ALK, MET and ROS1. In a safety database trial, it was suggested an association of Crizotinib with the development of renal cyst in patients with non-small-cell lung cancer (NSCLC). Aim: To report an uncommon side effect of Crizotinib in a patient with NSLC. Case Presentation: We report the case of a 68-year-old woman with NSCLC who developed bilateral progressive aseptic renal abscesses during Crizotinib treatment. Conclusion: Further studies may be necessary to determinate the risk of renal cyst development and the management of these complications.

show abstract

“…Po vysazení crizotinibu došlo k normalizaci eGFR k hodnotám před zahájením léčby. Etiologie této toxicity může úzce souviset s vyšší pravděpo-dobností vzniku nových a ve zvětšení již přítomných cyst ledvin [29,30].…”

Section: Inhibitory Alkunclassified

Cancer Treatment-induced Changes in Renal Function in Patients with Tumors – Update on Current Knowledge

Pokrivčák¹,

Poprach²

2018

Klin Onkol

View full text Add to dashboard Cite

Klinika komplexní onkologické péče, Masarykův onkologický ústav, Brno SouhrnVýchodiska: Abnormality funkce ledvin spojené s přítomností malignity bývají poměrně časté. Různě vyjádřená porucha renální funkce je přítomná přibližně u cca 60 % pa cientů s nádorem. Poškození ledvin může vznikat buď v důsledku přímého nebo nepřímého působení tumoru na ledviny a močové cesty. Systémová onkologická terapie může svůj negativní vliv na renální funkce uplatnit opět dvojím způsobem -přímým toxickým působením na strukturu ledvin a nepřímo v důsledku dehydratace nebo "tumor lysis syndromu". Od roku 2004 byla Food and Drug Administration schválena do klinického užití v terapii solidních nádorů řada potenciálně nefrotoxických chemoterapeutik, cílených léků a imunoterapeutik. Cíl: V rámci tohoto souhrnného článku přinášíme přehled nejnovějších informací týkajících se nefrotoxicity u nově používaných léků. Závěr: I přes nástup nových typů léků zahrnujících cílenou terapii a imunoterapii přetrvává riziko postižení ledvin. Mechanizmus vzniku je odlišný od klasické chemoterapie a většinou se jedná o toxicitu mírného nebo středního stupně. V klinických studiích nejsou ve většině případů zastoupení pa cienti s preexistující renální insuficiencí, a proto může být její vý-skyt v rutinní praxi vzhledem k vysoké prevalenci chronického onemocnění ledvin u onkologických pa cientů vyšší. Zhoršení renálních funkcí může významným způsobem ovlivnit strategii léčby, a proto je pečlivá monitorace renálních funkcí nedílnou součástí každé klinické kontroly. Klíčová slova renální selhání -toxicita -imunoterapie -chemoterapie SummaryBackground: Renal abnormalities associated with malignancy are common with renal impairment occurr ing in about 60% of patients with tumors. Kidney dis ease may occur as a result of direct or indirect effects of tumors on kidneys and the urinary tract. Systematic oncology treatment can affect renal function in two ways, via direct toxic effects on kidney structure and indirectly via dehydration or tumor lysis syndrome. Since 2004, the Food and Drug Administration has approved a number of potentially nephrotoxic chemotherapeutics, targeted drugs, and immunotherapeutics for the treatment of solid tumors. Aim: This article provides an overview of the latest information on the nephrotoxicity associated with the use of new drugs. Conclusion: Despite the development of new drug treatments, includ ing targeted ther apy and immunother apy, the risk of kidney involvement persists. The mechanisms of action of these new drugs are different from those of classical chemother apy, and their use is usually associated with only mild to moderate side effects. In clinical trials, patients with pre-exist ing renal insufficiency are not present in most cases. Deterioration of renal function may significantly affect the treatment strategy and therefore careful renal function monitor ing should be an integral part of each clinical trial.

show abstract

Development of Renal Cysts after Crizotinib Treatment in Advanced ALK-Positive Non–Small-Cell Lung Cancer

Abstract: Change of renal cysts after crizotinib treatment is not uncommon. Development of complex renal cysts reverses after stopping crizotinib.

Cited by 56 publications

References 13 publications

Renal Toxicities of Targeted Therapies

Renal Toxicities of Targeted Therapies

Development of Aseptic Renal Abscess in a Patient with Non-Small-Cell Lung Cancer with ALK Translocation during Crizotinib Treatment

Cancer Treatment-induced Changes in Renal Function in Patients with Tumors – Update on Current Knowledge

Contact Info

Product

Resources

About